The sale of the controlling interest in the insurance platform represents a significant and rapid return on investment for White Mountains.
With a potential market of 128 million in the U.S., analysts see blockbuster potential for the new presbyopia treatment.
Positive Phase 1 results for the company's epilepsy drug candidate are coupled with a significant financing deal that could dilute shares.
Tecentriq in combination with Zepzelca approved as a first-line maintenance treatment for extensive-stage small cell lung cancer, a significant advancement for a hard-to-treat cancer.
Disruption at a key California facility could tighten fuel markets, boosting margins for competing refiners in an already vulnerable region.
The approval covers a first-line maintenance treatment for an aggressive form of small cell lung cancer, a historically difficult-to-treat disease.
The regulator's green light for Rhapsido, a first-in-class oral treatment for chronic hives, positions the company to challenge injectable rivals.
All-stock deal aims to create a diversified semiconductor equipment leader, though Axcelis shares dip on the news.